General Information
This Website contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech, including projections and forecasts relating to our operations and financial situation, statements about the future development of satraplatin and our other drug candidates, the potential efficacy and safety profile of satraplatin and our ability to successfully complete any M&A or partnering transaction. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors. In particular, there can be no guarantee that satraplatin will be approved in Europe or elsewhere or that a new registrational path with respect to satraplatin will be found that can be completed within a reasonable timeframe, if at all. We may also not be successful in identifying and successfully completing any M&A or partnering transaction. We caution investors not to place undue reliance on the forward-looking statements contained in this Annual Report. We direct you to GPC Biotech’s Annual Report on Form 20-F for the fiscal year ended December 31, 2007 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech.
Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Satraplatin has not been approved by the EMEA in Europe, the FDA in the U.S., or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.
